Table 1 Baseline characteristics of the participants.
Number of patients | 537 |
Male (%) | 387 (72.1%) |
Female (%) | 150 (27.9%) |
Age (years) | 73.11 ± 8.43 |
History of CSC (%) | 28 (5.2%) |
LogMAR BCVA in CNV-affected eye | 0.322 ± 0.363 |
Axial length in CNV-affected eye (mm) | 23.62 ± 1.09 |
Retinal thickness in CNV-affected eye (μm) | 402.80 ± 208.10 |
Choroidal thickness in CNV-affected eye (μm) | 259.15 ± 108.94 |
Choroidal thickness in fellow eye (μm) | 255.94 ± 104.79 |
CVH (+) in either eye (%) | 125 (23.3%) |
Polypoidal region (+) in CNV-affected eye | 254 (47.3%) |
Choroidal vessel dilation (+) in either eye | 293 (54.6%) |
Reduced fundus tessellation (+) in either eye | 233 (43.4%) |
Pseudodrusen (+) in either eye | 29 (5.4%) |
Type A drusen (+) in either eye | 93 (17.3%) |
Type B or C drusen (+) in either eye | 337 (62.8%) |